Anna Collén

Anna holds a PhD in Biochemistry at Lund University and joined AstraZeneca in 2001. Before joining AZ Anna spent time at a small biotech in Copenhagen, ALK with antigen production for immunization of humans and one of the world leading technology institutes, VTT in Helsinki, Finland with large scale protein production in collaboration with Genencore, US. Anna has held a number of increasingly senior positions at AstraZeneca within Therapy Areas early science units, spanning from early discovery to late development and life cycle management. Anna is in the last 5 years involved in the mRNA project in collaboration with Moderna where she currently is the project lead for the novel project utilizing mRNA encoding for VEGF for cardiac regeneration.